drugset / Trial / NCT00185328

Efficacy and Tolerability of Angeliq in Thai Women

NCT00185328

Phase 4 Completed 55 enrolled Bayer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate the safety, tolerability, and efficacy of Angeliq in Thai post menopausal women with hot flushes and other climacteric symptoms.

Timeline

Start
2005-09
Primary completion
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Estradiol Other / unclassified 1 mg Oral
Subject drospirenone Unknown 2 mg Oral

Indications

No indication recorded.